Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
45.10
-1.81 (-3.86%)
At close: Jul 21, 2025, 4:00 PM
45.55
+0.45 (1.00%)
After-hours: Jul 21, 2025, 7:58 PM EDT
TNXP Employees
Tonix Pharmaceuticals Holding had 81 employees as of December 31, 2024. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$123,963
Profits / Employee
-$1,628,716
Market Cap
334.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
TNXP News
- 19 hours ago - Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia - GlobeNewsWire
- 11 days ago - Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 - GlobeNewsWire
- 12 days ago - Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - GlobeNewsWire
- 14 days ago - Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 - GlobeNewsWire
- 19 days ago - Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy - Seeking Alpha
- 5 weeks ago - Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 - GlobeNewsWire